Genius Biotherapeutics Overview
- Year Founded
-
1982
- Status
-
Out of Business
- Employees
-
11
- Latest Deal Type
-
Out of Business
- Financing Rounds
-
3
- Investments
-
1
Genius Biotherapeutics General Information
Description
Operator of a biotechnology company intended for making pharmaceutical products. The company's monoclonal antibody technology is focused principally on the enhancement of cellular immune response in humans through quality, cost-effective, and modern biotechnology products for human pharmaceutical use.
Contact Information
Website
www.bioclones.co.zaCorporate Office
- 86 Oak Avenue
- High Veld Technopark
- Centurion, 8000
- South Africa
Corporate Office
- 86 Oak Avenue
- High Veld Technopark
- Centurion, 8000
- South Africa
Genius Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Genius Biotherapeutics Comparisons
Industry
Financing
Details
Genius Biotherapeutics Competitors (37)
One of Genius Biotherapeutics’s 37 competitors is Kaneka Eurogentec, a Formerly PE-Backed company based in Seraing, Belgium.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kaneka Eurogentec | Formerly PE-Backed | Seraing, Belgium | ||||
| Novavax | Corporation | Gaithersburg, MD | ||||
| Cytovance Biologics | Formerly PE-Backed | Oklahoma City, OK | ||||
| GeneTex | Formerly VC-backed | Irvine, CA | ||||
| Lonza Group | Corporation | Basel, Switzerland |
Genius Biotherapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Genius Biotherapeutics Patents
Genius Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2023052248-A | Dendritic cell maturation | Active | 14-Jul-2017 | ||
| DE-60209915-T2 | Process for the production of mature dendritic cells and a vaccine | Inactive | 08-Aug-2001 | ||
| ES-2263806-T3 | Procedure for the maturation of dendritic cells and a vaccine. | Inactive | 08-Aug-2001 | ||
| AU-2002324255-B2 | Process for the maturation of dentritic cells and a vaccine | Inactive | 08-Aug-2001 | ||
| CA-2457322-A1 | Process for the maturation of dentritic cells and a vaccine | Active | 08-Aug-2001 | C12N5/0639 |
Genius Biotherapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Genius Biotherapeutics Investments (1)
Genius Biotherapeutics’s most recent deal was a Buyout/LBO with Ribotech.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ribotech | Buyout/LBO | Pharmaceuticals |
Genius Biotherapeutics FAQs
-
When was Genius Biotherapeutics founded?
Genius Biotherapeutics was founded in 1982.
-
Where is Genius Biotherapeutics headquartered?
Genius Biotherapeutics is headquartered in Centurion, South Africa.
-
What is the size of Genius Biotherapeutics?
Genius Biotherapeutics has 11 total employees.
-
What industry is Genius Biotherapeutics in?
Genius Biotherapeutics’s primary industry is Biotechnology.
-
Is Genius Biotherapeutics a private or public company?
Genius Biotherapeutics is a Private company.
-
What is Genius Biotherapeutics’s current revenue?
The current revenue for Genius Biotherapeutics is .
-
How much funding has Genius Biotherapeutics raised over time?
Genius Biotherapeutics has raised $6M.
-
Who are Genius Biotherapeutics’s competitors?
Kaneka Eurogentec, Novavax, Cytovance Biologics, GeneTex, and Lonza Group are some of the 37 competitors of Genius Biotherapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
